After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from ...
Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
Dr Garg highlights new data showing that high-dose aflibercept could effectively extend treatment intervals, reducing the burden on patients, particularly working-age adults with busy schedules. Of ...
Indian drugmaker Biocon subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed ...
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...
EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) stock is trading higher on Monday after the company revealed interim 16-week data ...
The study comprised 161 patients split between three arms: EYP-1901 2mg (low dose; n=53); EYP-1901 3mg (high dose, n=54); and the standard of care, which was aflibercept 2mg every eight weeks (n=54).
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...
Chronic therapy is essential for PCV patients, even after resolution of pigment epithelial detachment, to prevent recurrence.
On September 19, 2024, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Sandoz’s aflibercept biosimilar AFQLIR.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback